EUVIMEDEUVIMED entdecken
Crossref

108 Real-World Comparison of sofosbuvir/velpatasvir vs. glecaprevir/pibrentasvir in an FQHC Population: Adherence and Treatment Outcomes

M. Edwards

Journal of the American Pharmacists Association · 2026-07 · 66 (4) · 103162

DOI: 10.1016/j.japh.2026.103162 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Pharmacists Association, 2026-07. Verfasst von M. Edwards.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Edwards, M. (2026). 108 Real-World Comparison of sofosbuvir/velpatasvir vs. glecaprevir/pibrentasvir in an FQHC Population: Adherence and Treatment Outcomes. Journal of the American Pharmacists Association, 66(4), 103162. https://doi.org/10.1016/j.japh.2026.103162

Vancouver

Edwards M. 108 Real-World Comparison of sofosbuvir/velpatasvir vs. glecaprevir/pibrentasvir in an FQHC Population: Adherence and Treatment Outcomes. Journal of the American Pharmacists Association. 2026;66(4):103162. doi:10.1016/j.japh.2026.103162

BibTeX
@article{Edwards2026,
  author = {Edwards, M.},
  title = {108 Real-World Comparison of sofosbuvir/velpatasvir vs. glecaprevir/pibrentasvir in an FQHC Population: Adherence and Treatment Outcomes},
  journal = {Journal of the American Pharmacists Association},
  year = {2026},
  volume = {66},
  number = {4},
  pages = {103162},
  doi = {10.1016/j.japh.2026.103162}
}
Kostenlos starten →